

January 29, 2021

Senthil Sundaram
Chief Executive Officer
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Blvd., Suite 100
Foster City, California 94404

Pharmaceuticals, Inc.
Statement on Form S-1
2021

Re: Terns
Registration
Filed January 15,
File No. 333-252180

Dear Mr. Sundaram:

We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Form S-1 filed January 15, 2021

Management's Discussion and Analysis of Financial Condition and Results of Operations
Critical accounting policies and significant judgments and estimates
Common stock valuation methodology, page 105

1. In your response dated January 26, 2021, you noted that in October 2020 you reassessed the grant date fair value of all your grants made during the nine month period ended September 30, 2020. Your response does not address how you assessed the impact of the revaluation on your previously issued financial statements. If true, please revise your disclosure to confirm that you determined that the incremental stock compensation applicable to the historical quarterly periods was immaterial to those respective periods. In addition, revise your disclosure to quantify the aggregate number of options granted that were impacted by the retrospective valuation of your common stock as of

Senthil Sundaram
Terns Pharmaceuticals, Inc.
January 29, 2021
Page 2

September 1, 2020, the aggregate stock compensation to be recorded in the three month period ended December 31, 2020, and the incremental additional stock compensation expense that will be recorded in the three month period ended December 31, 2020 as a result of this retrospective valuation.

Notes to Unaudited Condensed Consolidated Financial Statements
14. Subsequent Events, page F-57

2. We note that the December 2020 option grant appears to be included in disclosure

provided in Item 15. Recent Sales of Unregistered Securities: Equity
Plan-Related

Issuances on page II-2. Further, you state in your response dated January
26, 2021 that

you anticipate using the initial public offering price as the grant date
fair value for your

grant of options in December 2020. Please revise Note 14 to disclose all
of the relevant

information regarding your grant of options in December 2020, including
how you intend

to value these options.

We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

You may contact David Burton at 202-551-3626 or Sasha Parikh at
202-551-3627 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Chris Edwards at 202-551-6761 or Celeste Murphy at 202-551-3257 with
any other
questions.

FirstName LastNameSenthil Sundaram
Corporation Finance
Company NameTerns Pharmaceuticals, Inc.

Sciences
January 29, 2021 Page 2
cc: Brian Cuneo
FirstName LastName

Sincerely,
Division of
Office of Life